present in 40 control patients with other neurodegenerative diseases. The aberrantly processed RNAs detected in ALS patients are all related to EAAT2; the aberrant transcripts and concomitant loss of EAAT2 protein were only found in motor cortex and spinal cord; and an S1 Based on this evidence, the hypothesis that the majora gene can lead to inappropriate pairing of 5Ј and 3Ј ity of sporadic cases of ALS are due to malfunctioning splice sites resulting in exon skipping, or to the recognisplicing factor(s) is likely to be correct. However, it tion of "cryptic" 5Ј and 3Ј splice sites producing abershould be noted that the data are correlative rather than rantly spliced RNAs. In addition to this mechanism, constituting proof by causation, and alternative hypothRothstein and colleagues observed a second phenomeeses could conceivably be formulated. An additional non: a defect in the splicing machinery (not in the gene) problem involves testing the hypothesis by expression that leads to the use of inappropriate 5Ј and 3Ј splice of transfected cDNAs in COS cells. Under these condisites (often called donor and acceptor sites for splicing, tions, genes are greatly overexpressed compared to respectively). This gives rise to additional abnormal trannormal cells. Such overexpression can cause artifacts scripts and constitutes an apparently new concept in in localization of proteins. The authors used this in vitro disease pathogenesis. The disease discussed here is expression system to show that EAAT2 mRNA underamyotrophic lateral sclerosis (ALS or Lou Gerhig's disgoes rapid degradation and that the intron 7-retenease), with sporadic or nonfamilial patients accounting tion RNA causes a dominant-negative effect on normal for approximately 95% of ALS cases worldwide. Pre-EAAT2, resulting in loss of protein and activity. Nonetheviously, it was known that 5% of cases were inherited less, aberrant exon 9-skipping transcripts appear to be in an autosomal-dominant manner, and ‫%1ف‬ of cases the most abundant in some ALS patients but have no were due to mutations of the Cu 2ϩ /Zn ϩ superoxide diseffect on overexpressed EAAT2 protein in COS cells. mutase gene (Rosen et al., 1993) . The Rothstein group Stable transfections of cells normally expressing EAAT2 had already shown that 60%-70% of patients with spowould yield a more reliable system in which to test the radic ALS display a loss of the astrocytic glutamate hypothesis that the aberrantly expressed transcripts aftransporter protein EAAT2 in motor cortex and spinal fect EAAT2 activity. An even more critical test of the cord (Rothstein et al., 1995) . This finding supported an hypothesis will come from transgenic mice manifesting 'excitotoxic' hypothesis for most cases of ALS, with tissue-specific expression of the aberrant RNAs and neurons dying by overexcitation due to excessive glutamay offer proof of the model that aberrant splicing conmate receptor stimulation and the resulting oxidative or tributes to this neurodegenerative disorder. However, nitrosative stress. The important point of the paper in examination of full-length PCR products shows that ALS this issue of Neuron is that the data imply (but do not patients often have many abnormal RNA species and not definitively prove) that there is a specific defect in EAAT2 just exon 9 skipping or intron 7 retention, so a detailed mRNA splicing in ALS tissue. This defect does not apmechanistic pathogenesis is still lacking. pear to result from a mutation in the EAAT2 gene itself, How can we understand how abnormal mRNA splicing as seen in alleles of many other disease genes. Nor does could arise and exactly what steps are involved? For the problem appear to arise from an abnormality in the about 20 years, we have known that most genes in general splicing apparatus such as the spliceosome beeukaryotic cells are interrupted by introns, often comcause splicing of other non-EAAT2 transcripts is not prised of very large sequences. During transcription, affected. Rather, the findings may imply a defect in a DNA polymerase II transcribes an entire gene to produce splicing regulatory factor that is only required for splicprecursor mRNA (pre-mRNA). Nascent pre-mRNA uning relatively few transcripts, presumably including dergoes RNA processing; this includes precise splicing EAAT2.
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out of the intronic sequences and ligating together the Rothstein and colleagues report the presence of abersequences encoded by exons that on average are much rant RNAs in 65% of sporadic ALS cases based on smaller (mean, 137 bp per exon) (Berget, 1995) . Splicing examinations of 30 patients. Aberrant RNAs were not occurs concurrently with transcription. The splicing reaction is carried out by the spliceosome, a multicomponent complex containing over 70 proteins and 5 small nuclear RNAs (Will and Lü hrmann, 1997) . The spliceoAlternative RNA splicing can produce physiological variants in proteins by selectively including or excluding some is assembled in a stepwise manner, and the correct 5Ј and 3Ј splice sites are recognized by specific particular exons. Sequences flanking the splice donor and acceptor sites or located in neighboring introns or components of the spliceosome during the earliest stage of spliceosome assembly. The 5Ј donor splice site exons can influence the activity of the splice sites (Reed, 1996) . A "weak" site may result in exon skipping (excluincludes an initial intronic dinucleotide that is invariant (GT [or GU if considering the pre-mRNA sequence]); the sion) (Berget, 1995) . Pre-mRNA splicing is a highly regulated process. Recent findings indicate that cis elements 3Ј acceptor splice site has an intronic sequence ending in the invariant dinucleotide AG ( Figure 1A ). Spliceolocated in exons and introns, termed exonic splicing enhancers (or ESEs) and intronic splicing enhancers (or some assembly is a dynamic process, ultimately leading to the accurate positioning of the 5Ј and 3Ј splice sites ISEs), interact with trans-acting factors (e.g., activators) to regulate the recognition of splice sites and the rate for cleavage of the intron and ligation of the exons (Staley and Guthrie, 1998). Assembly of the spliceosome of the splicing. However, not all splicing regulator sequences are splicing enhancers, for example, those that begins on the RNA as it is synthesized. After other RNA processing events occur in the nucleus (e.g., 5Ј capping, bind repressor proteins. SR (serine-arginine-rich) proteins and other RNA binding proteins are involved in 3Ј polyadenylation, and editing), mRNA is "mature" and ready for exportation into the cytoplasm to serve as a the regulation of alternative splicing and serve as trans factors (Cooper and Mattox, 1997; Wang and Manley, template for translation. Recently, a small group of introns has been found to have different consensus dinu-1997).
Single mutations of the invariant dinucleotides or cleotides at 5Ј splice donor and 3Ј acceptor sites (AT [or AU for pre-mRNA] and AC, respectively). Their splicing flanking sequences of splice sites may change the pattern of splicing (Nakai and Sakamoto, 1994 ; Berget, involves the same reactions as the majority of introns, but uses different small nuclear RNAs (Tarn and Steitz, 1995; Cooper and Mattox, 1997) . Mutations of ESEs or ISEs may also change the splicing pattern (Cooper and 1997). All of these proteins represent potential targets for disease processes. One example is SMN (survival Mattox, 1997). Hence, genomic mutations (point mutations, insertions, or deletions) of these splice-related motor neuron) protein, apparently involved in assembly of the small nuclear RNAs, which has recently been donor, acceptor, and enhancer site sequences can cause abnormal alternative splicing. In fact, several hufound to be lost in another motor neuron disease, spinal muscular atrophy (Liu et al., 1997) .
man diseases have been shown to be caused or at least correlated with the loss of functional protein activity In sporadic cases of ALS, why does the aberrant RNA due to abnormal splice variants arising from genetic or processing occur only in EAAT2 pre-mRNA, and why somatic mutations of splice-related sequences (Nakai only in the motor cortex and spinal cord? There are as and Sakamoto, 1994; Cooper and Mattox, 1997) . As an yet no clear answers to these questions. We know that example of a genetic disease, historically the first splicmotoneurons are very active metabolically and therefore ing mutations recognized were found in the ␤-globin could be readily subjected to oxidative or nitrosative gene of patients with ␤-thalassemia, some of which restress. A unifying hypothesis might therefore invoke sult in the activation of cryptic splice sites producing stress-related damage to the aforementioned protein(s) either partial exon deletion or intron retention (Treisman responsible for RNA splicing. However, it is an astrocytic et al., 1983). Patients with hereditary vitamin D-resistant glutamate transporter rather than a neuronal transporter rickets display inherited mutations in the donor splice that is affected, so the link to neuronal stress is not a site on intron 4 of the vitamin D3 receptor gene. This direct one. Moreover, why such a mechanism should mutation causes skipping of exon 4 and results in a specifically affect EAAT2 mRNAs while leaving trannonfunctional receptor for vitamin D. Another example scripts encoding other proteins unaffected remains a is a somatic mutation of the genome encoding the P53 mystery. Alternatively, some additional mRNAs whose gene in some patients with liver cancer. Additionally, a splicing is abnormally regulated by damage to a specific nonsense mutation of an ESE in the dystrophin gene splice-related factor could be affected in these sporadic causing upstream exon skipping results in Becker muscases of ALS, and we just do not know the identity of cular dystrophy (Shiga et al., 1997) . These diseases all these other mRNAs as yet. appear to be produced by mutations in the spliceFinally, in at least one of Rothstein's ALS patients related sequences but use a normal mechanism of splic-(Case #3) with abnormal EAAT2 RNAs, several of the ing ( Figure 1B ). In contrast, the Rothstein group mounts PCR products were found to migrate on agarose gels evidence that ALS is associated with an abnormal splicas a single band but actually represented a mixture of ing process for EAAT2 pre-mRNA that can skip normal RNAs. Thus, the presence of a "normal" level of mRNA 5Ј donor and 3Ј acceptor sites ( Figure 1B, top half) or evidenced by a single band on a Northern blot or RTutilize inappropriate 5Ј and 3Ј splice sites (i.e., other than PCR in the face of a low level of cognate protein does the normal GU or AU for the donor site, and AG or AC not exclude an abnormal mechanism of RNA processing. for the acceptor site) ( Figure 1C ). In addition to aberrant This raises the possibility that in other diseases the partial intron-retention and exon-skipping transcripts, presence of multiple abnormal RNAs could easily be this abnormal splicing mechanism results in the appearoverlooked. ance of EAAT2 mRNAs that have been cleaved and In summary, many cases of sporadic ALS are correligated in exonic sequences at random sites. In other lated with aberrant RNAs caused by ignoring apparently words, previously, we knew that normal splicing could normal 5Ј and 3Ј splice sites, resulting in exon skipping result in aberrant RNAs and thus disease. The Rothstein and partial intron retention, and, to some extent, inapfindings extend our knowledge by showing that an abpropriate RNAs due to an abnormal splicing mechanism normal mechanism of splicing can also appear in a disusing random 5Ј and 3Ј splice sites. Further proof that eased state. The malfunction in the splicing mechanism this represents a pathogenesis of ALS using transgenic associated with ALS gives rise to multiple abnormal mice is anxiously awaited, e.g., expression of a partial RNAs in any given patient ( Figures 1B and 1C) . In conintron 7-retention mutant producing a dominant-negatrast, previously identified diseases associated with tive effect on EAAT2. However, final elucidation of the splice variants have encountered only a single or at most molecular pathogenesis of sporadic ALS may come not two aberrant RNAs in an affected patient (Nakai and from the expression of a single aberrant mRNA that Sakamoto, 1994; Cooper and Mattox, 1997) . The most reproduces the phenotype, but in cloning the postulated important point in the case of sporadic ALS is that there defective splicing regulatory factor and expressing it in seems to be a problem not in the EAAT2 gene itself transgenic mice. This approach should provide recapitthat gives rise to the aberrant splicing, but instead in a ulation of all of the features of the disease, including regulatory factor(s) that appears to be at least somewhat the interesting pattern of aberrant mRNAs present in specific for EAAT2 transcripts.
any single patient. Aberrant RNAs have become so abundant that Nakai and Sakamoto in 1994 established an aberrant splicing database (Web site: http://www.imcb.osaka-u.ac.jp/ Acknowledgments nakai/asdb.html). They have collected more than 200 splice site mutations in 90 genes, most of them associWe wish to thank the anonymous referees of this review ated with human disease (Nakai and Sakamoto, 1994) .
who contributed greatly to the clarity of its message Exon skipping accounted for 50% of the mutations, (and hopefully avoided aberrancy). while intron retention was found in only 6%; other types of mutations resulted in activation of cryptic sites (repreSelected Reading senting normal sequences but weak activity) or creation of pseudo exons from introns. Most of these mutations Berget, S.M. (1995) . J. Biol. Chem. 270, 2411 -2414 result in nonfunctional proteins. Other Web addresses Cooper, T.A., and Mattox, W. (1997) . Am. J. Hum. Genet. 61, [259] [260] [261] [262] [263] [264] [265] [266] listing splice site mutations can be accessed via the Krawczak, M., and Cooper, D.N. (1997) . Trends Genet. 13, 121-122. per, 1997).
